

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

ATTY. DOCKET NO.
2503-1033

SERIAL NO.
10/009,501

APPLICANT
Josee GOLAY et al.

FILING DATE
May 6, 2002

GROUP
1644

O I P E CFR 1.98(b)
LAPS
NOV 22 2005

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA						
AB						

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NO.	PUBL. DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANSLATION YES NO
AC						
AD						

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

AE	McLaughlin, Peter et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program", <u>Journal of Clinical Oncology</u> , Vol. 16, pp. 2825-2833. XP-002149247
AF	
AG	
AH	
AI	
AJ	

EXAMINER**DATE CONSIDERED**

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.